2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
2
Genitourinary
2
Tumor-Agnostic
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
623
Radiotherapy
411
Bevacizumab
257
Magnetic Resonance Spectroscopy
227
Cyclophosphamide
179
Radiosurgery
163
Carboplatin
160
Etoposide
132
Radiation
129
Vincristine
115
Irinotecan
115
Cisplatin
103
Filgrastim
100
Specimen Handling
90
Nivolumab
88
pembrolizumab
84
Surgical Procedures, Operative
83
Lomustine
83
Topotecan
73
Doxorubicin
61
Melphalan
59
Carmustine
57
Radiotherapy, Intensity-Modulated
56
sargramostim
53
Isotretinoin
53
Peripheral Blood Stem Cell Transplantation
52
Granulocyte Colony-Stimulating Factor
51
Chemotherapy, Adjuvant
51
Blood Specimen Collection
51
Erlotinib Hydrochloride
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
cabiralizumab
×
CNS
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts